practice, treatment patterns and outcomes of patients with CLL have not been previously assessed.
Fludarabine-based combination therapy is the cornerstone of first-line treatment for physically fit patients with CLL, being previously used exclusively in combination with cyclophosphamide (fludarabine-cyclophosphamide, FC), 6 and today recommended in combination with both cyclophosphamide and the monoclonal anti-CD20 antibody rituximab (fludarabine-cyclophosphamide-rituximab, FCR). 7, 8 Over time, the choice of first-line treatment in patients unfit for FC/FCR has shifted from chlorambucil or cyclophosphamide 9 to bendamustine combined with rituximab (BR) or chlorambucil combined with a monoclonal anti-CD20 antibody. Second-line treatment with monoclonal antibodies has also become recommended. 7, 8 Since 2014, B-cell receptor (BCR) inhibitors have been used as targeted treatments for certain patients with CLL, at first and later lines. 7, 8 Over time, Finnish treatment guidelines 10 have aligned with the international recommendations. 7, 8 Observational data from routine clinical practice enable investigation into how recommended treatment guidelines are utilised and helps in assessing the effects of therapies more broadly than in randomized controlled trials. 11 Prior studies with real-world data have reported the overall survival (OS) from CLL diagnosis improving over time. 3, [12] [13] [14] However, a population-based study in Sweden 15 did not find significant improvement over time in second-line outcomes, despite the increased use of novel therapies, including chemoimmunotherapy. Temporal trends have been studied until 2013, 2, 3, [12] [13] [14] [15] after which BR became more established as a standard first-line option for elderly patients. Furthermore, these investigations in time trends using real-world data did not adjust for differing clinical characteristics and treatments, 2, 3, [12] [13] [14] [15] leaving the influence of these factors on treatment outcomes unknown.
The objectives of this study were to describe treatment patterns for patients with CLL in first-and second-line routine practice settings at the Helsinki University Hospital, Finland, to compare the OS and time-to-next-treatment (TTNT) between patients treated in different time periods (2005-2008, 2009-2013, 2014-2015) , and to explore factors associated with OS and TTNT.
| MATERIAL S AND ME THODS
This was an observational retrospective cohort study using existing register data from the Finnish Hematology Registry (FHR). 16 The FHR was created to collect routine clinical practice outcomes in patients with CLL and other haematological malignancies, enabled by Finland's centralised nationwide healthcare system for reliable patient identification and comprehensive follow-up.
From the FHR, adult patients (≥18 years) diagnosed with CLL
were included in this study if they received one or more treatment lines during 2005-2015 at the Helsinki University Hospital, Finland, a hospital region accounting for 26% of the national CLL incidence. 5 Each included patient was followed-up from the date of first-line CLL treatment initiation (1st January 2005 -31st December 2015), until the end of follow-up, defined as the end of study period (31st December 2015) or death, whichever came first. For this study, patients were divided into three mutually exclusive groups based on each patient 's time of initiating the first-and subsequently secondline treatment: 2005-2008, 2009-2013 or 2014-2015, referred to as the early, middle, or late time periods, respectively.
All study variables were extracted as available from the FHR, including the following patient characteristics at the initiation of firstline and second-line treatments: age, gender, Binet stage, cytogenetic lesions using the fluorescence in situ hybridization (FISH) test, immunoglobulin heavy chain variable (IgHV) mutational status, comorbidity index, blood leukocyte count, year of CLL diagnosis, and time to progression (ie time between first-line end and second-line treatment initiation, for second-line only). The comorbidity index was derived according to Charlson, 17 as applicable with FHR data (Appendix S1).
Treatment regimens at first-and second-line were categorised into the following mutually exclusive categories:
• Fludarabine-cyclophosphamide or fludarabine-cyclophosphamiderituximab (FC/FCR)
• Bendamustine or bendamustine-rituximab (B/BR)
• Regimens other than FC/FCR or B/BR were, further divided into:
Chlorambucil without monoclonal antibody
Monoclonal antibody-based therapies alone or in combination (other than FCR or BR). Among them, chlorambucil-based therapies were described separately Other treatments, including therapies with glucocorticoids, cyclophosphamide or fludarabine, excluding therapies in any of the other categories BCR inhibitors were not used as first-or second-line treatments during the study period and were seldom used in subsequent treatment lines for this population (4 patients), as idelalisib-rituximab was reimbursed in Finland in October 2015, and ibrutinib was available only with special permission during the study period.
The OS and TTNT were assessed from the initiation of first-or second-line treatments. Patient characteristics and treatment regimens at first-and second-line were reported descriptively for all included patients at first-and second-line, and stratified by the treatment initiation period. The outcomes were explored with the Kaplan-Meier estimator and differences in survival distributions were compared using the log-rank test. Outcomes between the time periods were further compared using a multivariate Cox model adjusted for patient characteristics at the start of first-or second-line treatment and the treatment regimen given within the treatment line (FC/FCR, B/BR, or other). In the Cox models, factors associated with OS and TTNT were also explored, and the analysis of second-line treatment was adjusted for the first-line treatment. The adjusted Cox model results were presented as hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs). Missing data for variables were described and used without imputation in the analyses (see Appendix S1 for more details). R software 3.1.1 was used.
The study was performed in accordance with the declaration of 
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| RE SULTS

| Patient characteristics in first-line
| Patient characteristics in second-line
During the study, 64 patients initiated second-line treatment: 6 in the early, 41 in the middle and 17 in the late period ( Table 1 ). The median age was 71 years, with little variation between the time periods.
The use of FISH testing before second-line treatment increased over time from 50% (3/6) of patients in the early period to 88% (15/17) in the late period. The IgHV mutation status was not tested in the early period, and was available for a minority of patients in the mid- 
| Treatment patterns in first-line
The most frequently used first-line treatments (>50% of patients)
were FC/FCR irrespective of the treatment initiation period ( 
| Treatment patterns in second-line
Second-line treatment with FC/FCR varied from no patients in the early to 24% (10/41) in the middle and 12% (2/17) in the late period ( TA B L E 1 (Continued)
| Overall survival in first-line
The median OS after any first-line treatment initiation was 82 months (95% CI 73-not available). When the treatment was initiated in the early period, median OS was 77 months, while the median OS was not reached for the late and middle periods ( Figure 1A) . Based on the adjusted Cox regression model ( 
| Overall survival in second-line
For all 64 patients who received second-line treatment, the median OS was 37 months (95% CI (24 months), without reaching statistical significance ( Figure 1B) . (Table 3) .
| Associated factors
Other factors increasing the risk of death after first-line treatments included higher age, comorbidity index and leukocyte count (Table S1 in Appendix S2). These factors were not associated with second-line OS.
| Time-to-next-treatment
The median first-line TTNT for all patients was 45 months (95% CI 40-63), with a statistically non-significant improvement from the early to middle period ( Figure 1C ). After adjustment for other factors, TTNT was found to be longer for patients initiating first-line treatment in the middle vs early period (adjusted HR 0.36, 95% CI 0.15-0.87) ( Table 2 ). The corresponding results for the late period were not available as no one proceeded to the next treatment during the follow-up.
The median second-line TTNT was 19 months, without signs of time trend between the periods ( Figure 1D ; all comparisons nonsignificant). When adjusting for other factors in the Cox regression model, no association was observed between time period of secondline treatment initiation and TTNT ( Table 2 ).
The TTNT after first-line treatment initiation was shorter for patients with a higher comorbidity index and leukocyte count (Table S2 in Appendix S2). No factors were associated with TTNT after second-line treatment initiation. Treatment regimens were not associated with TTNT.
| D ISCUSS I ON
This study showed for the first time in Finland that patients with 
| Treatment patterns
We observed changes in first-line treatment practice over time, with increasing use of B/BR and decreasing use of chlorambucil-based therapies. FC/FCR were expectedly the most common first-line treatments throughout the study period, as FC was previously and FCR is today the recommended standard first-line treatment for fit patients with CLL, in the absence of del(17p). 7, 8 The 
| Overall survival
The trend towards improved survival for patients who initiated first-line treatment during the later years corroborates the results from real-world studies in Denmark, 14 Norway, 2 Germany and the United States. 3 The fact that in our study, the improved survival in Table S1 in Appendix S2.
TA B L E 3 Association between firstand second-line treatment regimens and overall survival (OS)
| Treatment regimens and overall survival
To our knowledge, this is the first observational study in routine clinical setting to report that first-line treatment with B/BR may result in inferior OS, compared to other regimens. A similar, statistically non-significant, trend towards inferior OS was observed with B/BR in second-line. These results were, however, likely influenced by other treatments and patient characteristics unexplored in this study. Although B/BR is commonly recommended, 8, 19 the evidence from clinical trials on its superiority as first-line treatment is limited. 20 Its evidence as second-line treatment is even more sparse, as the pivotal clinical study was a small single-arm phase 2 trial 21 and phase 3 studies have shown a poor effect of BR at relapse compared to novel agents. [22] [23] [24] Although a recent observational study concluded that BR is an effective salvage at first relapse, 25 
| Time-to-next-treatment
We found a trend towards delayed first-line TTNT when patients initiated treatment in the recent years. As for OS, the fact that the longer TTNT reached statistical significance in the adjusted analysis suggests that the improvement is dependent on multiple factors.
In contrast to first-line, second-line TTNT did not improve over time, a finding observed in the Swedish population as well. 15 This indicates that second-line treatments used in recent years may not prolong time to progression compared to the earlier treatments, thus warranting a need for optimising disease management in second-line.
| Other associated factors
Apart from treatment regimens, the other factors associated with first-line treatment outcomes in our study: higher comorbidity or lower performance status, 18, 26 higher leukocyte count, 27 and older age (associated with OS only), 18, [27] [28] [29] have also been identified previously as risk factors for shorter survival time and TTNT. Contrary to a prior study, 30 we did not identify short time to progression in the first-line as a risk factor for short survival in the second-line.
| Methodological considerations
This study is the first to report temporal trends in CLL treatment and outcomes after BR became a standard first-line option for elderly patients, and the first to investigate time trends using routine practices data with the possibility to adjust the analyses for differing clinical characteristics and treatments. The FHR data source enabled a more comprehensive detection of patients diagnosed with CLL and a wider range of patient and treatment characteristics, compared to exclusive use of the national cancer register. 2, 12, 14 This study was limited by a relatively small population and partially missing data for some key variables such as FISH and IgHV, limiting the full potential to control for confounding in the analyses. Moreover, data from one university hospital representing the metropolitan area were used, limiting the generalisability of the results to rural settings. In particular, elderly patients may have been under-represented in the study population as they are more likely to be treated outside of the university hospitals. This is also one reason for that the percentual proportion of FISH testing was lower than recommended in clinical practice in Finland, especially during the early years. As these biological data are in important role in ascertaining patient outcomes, improvements in diagnostic practices may have aided treatment selection in the recent, but not in the early years.
Finally, especially in second-line treated patients, a relatively small sample size coupled with limited follow-up, precluded reaching median OS and TTNT and the detection of statistically significant effects. 
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